文献速递妇科

美沙酮作为「抗癌」药物对卵巢癌细胞系及患者来源肿瘤球体的可疑效应

Dubious effects of methadone as an "anticancer" drug on ovarian cancer cell-lines and patient-derived tumor-spheroids.
PubMed 文献 · Gynecol Oncol · 2022-01-13

研究检测了170例卵巢癌组织及8株卵巢癌细胞系中OPRM1 mRNA表达,并在细胞系及4个患者来源肿瘤球体模型中评估D,L-美沙酮的促血管生成、细胞毒及凋亡效应。结果显示美沙酮可降低5株细胞系活力,但在2个球体模型中显著促进细胞生长(最高达121%),并在3个球体模型中减弱顺铂的抑制效应。

要点

  • 69%卵巢癌组织及3/8细胞系转录表达OPRM1,但OPRM1表达并非美沙酮作用的前提。
  • 美沙酮在5株细胞系中显著降低细胞活力,对凋亡及VEGF分泌无显著影响。
  • 2/4球体模型中美沙酮显著促进细胞生长(最高达121%),3个模型中减弱顺铂抑制效应。

核心结论

  • 部分卵巢癌样本表达OPRM1,但OPRM1并非D,L-美沙酮发挥功能的前提。
  • D,L-美沙酮可能通过刺激特定卵巢癌细胞生长及削弱顺铂疗效而产生有害效应。

研究设计与样本

  • 分析6株顺铂敏感、2株顺铂耐药卵巢癌细胞系、170例卵巢癌组织样本及12例非肿瘤对照组织的OPRM1 mRNA表达。
  • 在卵巢癌细胞系及4个患者来源肿瘤球体模型中评估D,L-美沙酮的促血管生成、细胞毒及凋亡效应。

主要发现

  • OPRM1在69%卵巢癌组织及3/8卵巢癌细胞系中转录表达。
  • D,L-美沙酮暴露显著降低5株卵巢癌细胞系的细胞活力,与OPRM1表达无关。
  • D,L-美沙酮单用或联合顺铂对细胞系凋亡或VEGF分泌无显著影响。
  • 4个球体模型中2个在D,L-美沙酮处理后细胞生长显著增强(最高达121%),长期暴露后尤为明显。
  • 加入D,L-美沙酮后,3个球体模型中顺铂的抑制效应减弱。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The opioid agonist D,L-methadone exerts analgesic effects via the mu opioid receptor, encoded by OPRM1 and therefore plays a role in chronic pain management. In preclinical tumor-models D,L-methadone shows apoptotic and chemo-sensitizing effects and was therefore hyped as an off-label "anticancer" drug without substantiation from clinical trials. Its effects in ovarian cancer (OC) are completely unexplored. METHODS: We analyzed OPRM1-mRNA expression in six cisplatin-sensitive, two cisplatin-resistant OC cell-lines, 170 OC tissue samples and 12 non-neoplastic control tissues. Pro-angiogenetic, cytotoxic and apoptotic effects of D,L-methadone were evaluated in OC cell-lines and four patient-derived tumor-spheroid models. RESULTS: OPRM1 was transcriptionally expressed in 69% of OC-tissues and in three of eight OC cell-lines. D,L-methadone exposure significantly reduced cell-viability in five OC cell-lines irrespective of OPRM1 expression. D,L-methadone, applied alone or combined with cisplatin, showed no significant effects on apoptosis or VEGF secretion in cell-lines. Notably, in two of the four spheroid models, treatment with D,L-methadone significantly enhanced cell growth (by up to 121%), especially after long-term exposure. This is consistent with the observed attenuation of the inhibitory effects of cisplatin in three spheroid models when adding D,L-methadone. The effect of methadone treatment on VEGF secretion in tumor-spheroids was inconclusive. CONCLUSIONS: Our study demonstrates that certain OC samples express OPRM1, which, however, is not a prerequisite for D,L-methadone function. As such, D,L-methadone may exert also detrimental effects by stimulating the growth of certain OC-cells and abrogating cisplatin's therapeutic effect.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Fiegl H, Hagenbuchner J, Kyvelidou C, et al. Dubious effects of methadone as an "anticancer" drug on ovarian cancer cell-lines and patient-derived tumor-spheroids. Gynecol Oncol. 2022. PMID: 35033381. doi:10.1016/j.ygyno.2022.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。